329 to 331, and at least one of a mutant linker having the amino acid sequence selected from the group consisting of SEQ ID NO: 306 to SEQ ID NO: 318, and a mutant C-terminus having the amino acid sequence selected from the group consisting of SEQ ID NO: 319 to SEQ ID NO: 328.

7. The disintegrin variant of claim 6, comprising the mutant RGD loop, the mutant linker and the mutant C-terminus.
8. The disintegrin variant of claim 1, comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 123, 124, 147, 149 and 171.
9. The disintegrin variant of any one of claims 1 to 8, wherein the disintegrin variant is pegylated or conjugated with albumin or Fc.
10. A polynucleotide encoding the disintegrin variant of any one of claims 1 to 9.
11. A recombinant host cell comprising a polynucleotide encoding the disintegrin variant of any one of claims 1 to 9.
12. A pharmaceutical composition comprising the disintegrin variant of any one of claims 1 to 9 and a pharmaceutically acceptable carrier.
13. The pharmaceutical composition of claim 12, which is for treating a disease associated with at least one integrin selected from the group consisting of αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1 integrins in a subject in need thereof.
14. The pharmaceutical composition of claim 13, wherein the integrin-associated disease is an angiogenesis-related eye disease selected from the group consisting of age-related macular degeneration, diabetic retinopathy, corneal neovascularizing diseases, ischaemia-induced neovascularizing retinopathy, high myopia, and retinopathy of prematurity.
15. The pharmaceutical composition of claim 13, wherein the integrin-associated disease is a cancer selected from the group consisting of metastatic melanoma, metastatic prostate cancer, metastatic breast cancer, colorectal carcinoma, liver cancer, ovarian cancer, cervical cancer, pancreatic cancer, non-small-cell lung cancer, and glioblastoma multiforme.
16. Use of a disintegrin variant of any one of claims 1 to 9 in the manufacture of a medicament for the treatment of a disease associated with at least one integrin selected from the group consisting of αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1 integrins in a subject in need thereof.